Spectrum Pharma (SPPI) Tops Q1 EPS by 6c

Spectrum Pharma (NASDAQ: SPPI) reported Q1 EPS of ($0.25), $0.06 better than the analyst estimate of ($0.31).

“Our top priority is submission of the NDA to the FDA for poziotinib based on the positive data from Cohort 2 of the ZENITH20 clinical trial,” said Joe Turgeon, President and CEO of Spectrum Pharmaceuticals. “The additional data on twice daily dosing presented at AACR has the potential to significantly expand the value of poziotinib. We also look forward to the FDA’s pre-approval inspection of the ROLONTIS manufacturing facility which has been scheduled for later this month.”

For earnings history and earnings-related data on Spectrum Pharma (SPPI) click here.

You May Also Be Interested In

• Vivos Therapeutics posts 35% revenue gain but widens net loss
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c
• Movano (MOVE) Misses Q2 EPS by 195c